Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
Revolution Medicines announced positive results from its Phase 3 RASolute 302 trial evaluating daraxonrasib in metastatic pancreatic cancer. The data was presented during the Plenary Session at the 2026 ASCO Annual Meeting, highlighting the significance of the findings.
Key figures
- Drug Name
- daraxonrasib
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.